Abstract
INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted. DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.
| Original language | American English |
|---|---|
| Pages (from-to) | 1421-1425 |
| Number of pages | 5 |
| Journal | American Journal of Gastroenterology |
| Volume | 119 |
| Issue number | 7 |
| Early online date | 27 Mar 2024 |
| DOIs | |
| State | Published - 1 Jul 2024 |
Keywords
- Janus kinase inhibitors
- acute severe ulcerative colitis
- ulcerative colitis
- upadacitinib
Fingerprint
Dive into the research topics of 'Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver